Selexipag (Uptravi)

The objective of this systematic review is to evaluate the beneficial and harmful effects of selexipag tablets for the treatment of pulmonary arterial hypertension (PAH) in adults (World Health Organization [WHO] FC II or III)

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health September 2017, 2017
Series:CADTH common drug review clinical review report
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01425nam a2200313 u 4500
001 EB001865301
003 EBX01000000000000001029381
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190504 r ||| eng
245 0 0 |a Selexipag (Uptravi)  |h Elektronische Ressource 
246 3 1 |a CDR clinical review report for Uptravi 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c September 2017, 2017 
300 |a 1 PDF file (53 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Acetamides / adverse effects 
653 |a Canada 
653 |a Antihypertensive Agents 
653 |a Acetamides / therapeutic use 
653 |a Hypertension, Pulmonary / drug therapy 
653 |a Pyrazines / adverse effects 
653 |a Pyrazines / therapeutic use 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review clinical review report 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK533864  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a The objective of this systematic review is to evaluate the beneficial and harmful effects of selexipag tablets for the treatment of pulmonary arterial hypertension (PAH) in adults (World Health Organization [WHO] FC II or III)